Efficacy of Intraoperative Low Dose Intravenous Amiodarone in Pharmacologic Cardioversion in Patients with Preoperative Atrial Fibrillation Presenting for Mitral Valve Replacement Surgery Randomized Control Trial
Pharmacological Intraoperative Cardioversion
DOI:
https://doi.org/10.1532/hsf.4901Keywords:
Mitral valve, amiodarone, replacement, arrhythmiaAbstract
Background: Atrial fibrillation (AF) is the most common form of dysrhythmia observed in the clinical field, causing multiple morbidities, such as thromboembolic complications. Hence, the maintenance of sinus rhythm is superior to rate control. This study tests the efficacy of single- and low-dose amiodarone on the persistence of AF after surgery before transfer to the intensive care unit.
Methods: A double-blinded, randomized controlled trial assessed 113 patients who underwent mitral valve surgery with preoperative chronic AF. Patients were divided into two groups: the control group (N = 55) who received 50 mL of 5% dextrose over 10 min after general anesthesia induction, and the amiodarone group (N = 58) who received 1 mg/kg of amiodarone diluted in 50 mL of 5% dextrose over 10 min shortly after anesthesia induction.
Results: The amiodarone group had a statistically significant successful conversion of preoperative AF to normal sinus rhythm in 40 patients (72.73%). The control group demonstrated spontaneous conversion from AF to a normal sinus rhythm in seven patients (12.73%). The sinus rhythm was maintained in 60% of patients (36), as four patients reverted to AF during the hospital stay despite the initial normal sinus rhythm after the operation. In contrast, 53 (96.36%) patients in the control group were discharged from the hospital with a controlled rate of AF. In addition, low-dose amiodarone caused a statistically significant reduction in heart rates at 10, 30, and 60 min after declamping, extended throughout the first 24 h with mean heart rates of 97.233±7.311, 99.509±8.482, and 97.940±7.715 bpm, respectively. In comparison, the control group had heart rates of 115.382±7.547, 115.055±13.919, and 113.618±8.765 bpm at these times. The mean postoperative heart rate at the end of the first 24 h was 97.793±7.189 bpm in the amiodarone group and 113.036±9.737 bpm in the control group. No mortality or need for mechanical support was recorded in either group.
Conclusions: Single and low-dose intraoperative intravenous amiodarone during mitral valve surgery may be practical to aid in pharmacological cardioversion of patients with preoperative chronic AF presenting for mitral valve surgery.
References
Ad N, Holmes SD, Massimiano PS, Rongione AJ, Fornaresio LM. 2018. Long-term outcome following concomitant mitral valve surgery and Cox maze procedure for atrial fibrillation. The Journal of Thoracic and Cardiovascular Surgery, vol. 155, no. 3, pp. 983–994, Mar.
Ad N, Suri RM, Gammie JS, Sheng S, O’Brien SM, Henry L. 2012. Surgical ablation of atrial fibrillation trends and outcomes in North America. The Journal of Thoracic and Cardiovascular Surgery, vol. 144, no. 5, pp. 1051–1060, Nov.
Andreasen F, Agerbæk H, Bjerregaard P, Gøtzsche H. 1981. Pharmacokinetics of amiodarone after intravenous and oral administration. Eur J Clin Pharmacol, vol. 19, no. 4, pp. 293–299, Jul.
Chokesuwattanaskul R, Shah N, Chokesuwattanaskul S, Liu Z, Thakur R. 2020. Low-dose Amiodarone Is Safe: A Systematic Review and Meta-analysis. Journal of Innovations in Cardiac Rhythm Management, vol. 11, no. 4, pp. 4054–4061, Apr.
Colunga Biancatelli RML, Congedo V, Calvosa L, Ciacciarelli M, Polidoro A, Iuliano L. 2019. Adverse reactions of Amiodarone. Journal of Geriatric Cardiology : JGC, vol. 16, no. 7, p. 552.
Echt DS and Ruskin JN. 2020. Use of Flecainide for the Treatment of Atrial Fibrillation. Am J Cardiol, vol. 125, no. 7, pp. 1123–1133, Apr.
Fuster V, et al. 2006. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation, vol. 114, no. 7, Aug.
Ghamrawy A, Ibrahim NN, Abd El-Wahab EW. 2020. How accurate is the diagnosis of rheumatic fever in Egypt? Data from the national rheumatic heart disease prevention and control program (2006-2018). PLoS Negl Trop Dis, vol. 14, no. 8, pp. 1–28, Aug.
Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B. 2000. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med, vol. 160, no. 12, pp. 1741–1748, Jun.
Hohnloser SH, et al. 1991. Electrocardiographic and antiarrhythmic effects of intravenous amiodarone: Results of a prospective, placebo-controlled study. American Heart Journal, vol. 121, no. 1, pp. 89–95, Jan.
Holt DW, Tucker GT, Jackson PR, Storey GCA. 1983. Amiodarone pharmacokinetics. Am Heart J, vol. 106, no. 4 Pt 2, pp. 840–847.
Je HG, et al. 2008. Impact of the Maze operation on the progression of mild functional tricuspid regurgitation. J Thorac Cardiovasc Surg, vol. 136, no. 5, pp. 1187–1192, Nov.
Kashima A, et al. 2005. Pharmacokinetic characteristics of amiodarone in long-term oral therapy in Japanese population. Biol Pharm Bull, vol. 28, no. 10, pp. 1934–1938, Oct.
King GS, Goyal A, Grigorova Y, Hashmi MF. 2022. Antiarrhythmic Medications. Seminars in Dialysis, vol. 3, no. 1, pp. 33–38, Feb.
Kotit S, Said K, ElFaramawy A, Mahmoud H, Phillips DIW, Yacoub MH. 2017. Prevalence and prognostic value of echocardiographic screening for rheumatic heart disease. Open Heart, vol. 4, no. 2, p. e000702, Dec.
Lombard FW and Liang Y. 2019. Risk Factors for Mitral Valve Surgery: Atrial Fibrillation and Pulmonary Hypertension. Seminars in Cardiothoracic and Vascular Anesthesia, vol. 23, no. 1, pp. 57–69, Mar.
Noubiap JJ, Nyaga UF, Ndoadoumgue AL, Nkeck JR, Ngouo A, Bigna JJ. 2020. Meta-analysis of the incidence, prevalence, and correlates of atrial fibrillation in rheumatic heart disease. Global Heart, vol. 15, no. 1, May.
Pollak PT, Bouillon T, Shafer SL. 2000. Population pharmacokinetics of long-term oral amiodarone therapy. Clin Pharmacol Ther, vol. 67, no. 6, pp. 642–652.
Raine D, Dark J, Bourke JP. 2004. Effect of mitral valve repair/replacement surgery on atrial arrhythmia behavior. The Journal of Heart Valve Disease, vol. 13, no. 4, pp. 615–621, Jul.
Rostagno C, Berioli MB, Stefàno PL. 2012. Treatment of Atrial Fibrillation in Patients Undergoing Mitral Valve Surgery. Atrial Fibrillation - Basic Research and Clinical Applications, Jan.
Roy D, et al. 2000. Amiodarone to Prevent Recurrence of Atrial Fibrillation. New England Journal of Medicine, vol. 342, no. 13, pp. 913–920, Mar.
Sarubbi B, Ducceschi V, Briglia N, Mayer MS, Santangelo L, Iacono A. 1998. Compared effects of sotalol, flecainide and propafenone on ventricular repolarization in patients free of underlying structural heart disease. Int J Cardiol, vol. 66, no. 2, pp. 157–164, Sep.
Selvaraj T, Kiran U, Das S, Chauhan S, Sahu B, Gharde P. 2009. Effect of single intraoperative dose of amiodarone in patients with rheumatic valvular heart disease and atrial fibrillation undergoing valve replacement surgery. Ann Card Anaesth, vol. 12, no. 1, pp. 10–16.
Shiga T, Tanaka T, Irie S, Hagiwara N, Kasanuki H. 2011. Pharmacokinetics of intravenous amiodarone and its electrocardiographic effects on healthy Japanese subjects. Heart and Vessels, vol. 26, no. 3, pp. 274–281, May.
Veronese M, McLean S, Hendriks R. 1988. Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method. Br J Clin Pharmacol, vol. 26, no. 6, pp. 721–731.
Wang B, Xu ZY, Han L, Zhang GX, Lu FL, Song ZG. 2013. Impact of preoperative atrial fibrillation on mortality and cardiovascular outcomes of mechanical mitral valve replacement for rheumatic mitral valve disease. Eur J Cardiothorac Surg, vol. 43, no. 3, pp. 513–519, Mar.
Wang CT, et al. 2020. Cox-maze III procedure for atrial fibrillation during valve surgery: A single-institution experience. Journal of Cardiothoracic Surgery, vol. 15, no. 1, pp. 1–6, May.
Wang J, et al. 2016. Impact of surgical ablation of atrial fibrillation on the progression of tricuspid regurgitation and right-sided heart remodeling after mitral valve surgery: A propensity-score matching analysis,” J Am Heart Assoc, vol. 5, no. 12, Dec.
Wyndham CRC. 2000. Atrial Fibrillation: The Most Common Arrhythmia. Texas Heart Institute Journal, vol. 27, no. 3, p. 257.
Published
How to Cite
Issue
Section
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).
